ZFYVE26

Across TCGA pan-cancer cohorts, ZFYVE26 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZFYVE26 data layer compared with 23 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZFYVE26 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZFYVE26 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

PDAC, UCEC, and GBM are the cancer types where ZFYVE26 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.243	0.518	.002	12	view →
UCEC	DFS	Median	II,III,IV	0.518	0.882	.030	8	view →
GBM	DFS	Quartile	All	0.604	0.793	.009	3	view →
CCRCC	OS	Median	All	1.000	0.916	.032	2	view →
HNSC	OS	Median	All	0.908	0.796	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZFYVE26–PDAC (DFS)

Open the PDAC breakdown →